Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

DSM to sell participation in DEXPlastomers JV to Borealis


DSM to sell participation in DEXPlastomers JV to Borealis

HEERLEN, NETHERLANDS -- (Marketwire) -- 11/12/12 -- Royal DSM, the global Life Sciences and Materials Sciences company, announced today that it has reached an agreement with Borealis AG for the sale of DEXPlastomers V.o.F, a 50/50 Joint Venture of DSM with an affiliate of ExxonMobil Chemical. DSM will also sell its LldPE Compact Solution Technology to Borealis. Subject to customary approvals and notifications, the transaction is expected to close in Q1 2013.

Established in 1996, DEXPlastomers is a 50/50 joint venture between DSM and Exxon Chemical Holland Ventures B.V., producing C8 plastomers and linear low density polyethylene. DSM's LldPE Compact Solution Technology was developed in the 1960's to produce polyethylenes in a certain density range and is instrumental to the operations of DEXPlastomers.

In 2012, DEXPlastomers anticipates sales of approximately EUR180 million. Currently, 95 DSM employees are in the scope of the transaction.

For DSM, a sale of DEXPlastomers is in line with its long-term focus of being a Life Sciences and Materials Sciences company, active in health, nutrition and materials. DSM's 50% participation in DEXPlastomers is reported under Corporate Activities in DSM's accounts.

DSM - Bright Science. Brighter Living.(TM)

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of around EUR9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

Press release-pdf:

http://hugin.info/130663/R/1656896/535781.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: DSM N.V. via Thomson Reuters ONE

[HUG#1656896]

DSM Corporate Communications Herman Betten tel. +31 (0) 45 5782017 fax +31 (0) 45 5740680 media.relations@dsm.com

DSM Investor Relations Dave Huizing tel. +31 (0) 45 5782864 fax +31 (0) 10 4590275 investor.relations@dsm.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement